Dysregulation of apoptosis in cancer

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2941-2953

  Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; FAS ANTIGEN; PROTEINASE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; APOPTOSIS; CANCER; CARCINOGENESIS; CELL DIVISION; CELL SURVIVAL; GENE MUTATION; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032877668     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2941     Document Type: Review

References (130)

1. Hengartner MO, Horvitz HR: Programmed cell death in Caenorhabditis elegans. Curr Opin Genet Dev 4:581-586, 1994
2. Yuan J, Shaham S, Ledoux S, et al: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75:641-652, 1993
3. Alnemri ES, Livingston DJ, Nicholson DW, et al: Human ICE/CED-3 protease nomenclature. Cell 87:171, 1996
4. Salvesen GS, Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell 91:443-446, 1997
5. Alnemri ES: Mammalian cell death proteases: A family of highly conserved aspartate specific cysteine proteases. J Cell Biochem 64:33-42, 1997
6. Zapata JM, Krajewski S, Huang R-P, et al: Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 47:129-140, 1998
7. Benjamin CW, Hiebsch RR, Jones DA: Caspase activation in MCF7 cells responding to etoposide treatment. Mol Pharmacol 53:446-450, 1998
8. Yamamoto H, Sawai H, Weber T, et al: Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res 58:997-1003, 1998
9. Wallach D, Boldin M, Varfolomeev E, et al: Cell death induction by receptors of the TNF family: Towards a molecular understanding. FEBS Lett 410:96-106, 1997
10. Yuan J: Transducing signals of life and death. Curr Opin Cell Biol 9:247-251, 1997
11. Yang X, Chang HY, Baltimore D: Autoproteolytic activation of pro-caspases by oligomerization. Mol Cell 1:319-325, 1998
12. Muzio M, Stockwell BR, Stennicke, HR, et al: An induced proximity model for caspase-8 activation. J Biol Chem 273:2926-2930, 1998
13. Landowski TH, Wu N, Buyuksal I, et al: Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266-4270, 1997
14. Yanagisawa J, Takahashi M, Kanki H, et al: The molecular interaction of Fas and FAP-1: A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem 272:8539-8545, 1997
15. Hitoshi Y, Lorens J, Kitada S, et al: Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity 8:461-471, 1998
16. Tschopp J, Thome M, Hofmann K, et al: The fight of viruses against apoptosis. Curr Opin Genet Dev 8:82-87, 1998
17. Wallach D: Placing death under control. Nature 388:123-126, 1997
18. Irmler M, Thome M, Hahne M, et al: Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195, 1997
19. Golstein P: Controlling cell death. Science 275:1081-1082, 1997
20. Hahne M, Rimoldi D, Schroter M, et al: Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274:1363-1366, 1996
21. O'Connell J, O'Sullivan GC, Collins JK, et al: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082, 1996
22. Bennett M, O'Connell J, O'Sullivan G, et al: The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160:5669-5675, 1998
23. Kastan M: On the TRAIL from p53 to apoptosis? Nat Genet 17:130-131, 1997
24. Owen-Schaub LB, Zhang W, Cusack JC, et al: Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15:3032-3040, 1995
25. Muller M, Strand S, Hug H, et al: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99:403-413, 1997
26. Wu GS, Burns TF, McDonald ER III, et al: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genetics 17:141-143, 1997
27. Eischen CM, Kottke TJ, Martins LM, et al: Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90:935-943, 1997
28. Yeh W, De La Pompa J, El-Deiry W, et al: FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:1954-1958, 1998
29. Chinnaiyan A, Chaudhary D, O'Rourke K, et al: Role of CED-4 in the activation of CED-3. Nature 388:728-729, 1997
30. Seshagiri S, Miller L: Caenorhabditis elegans CED-4 stimulates CED-3 processing and CED-3-induced apoptosis. Curr Biol 7:455-460, 1997
31. Zou H, Henzel WJ, Liu X, et al: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413, 1997
32. Li P, Nijhawan D, Budihardjo I, et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489, 1997
33. Liu X, Kim CN, Yang J, et al: Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome C. Cell 86:147-157, 1996
34. Yang J, Liu X, Bhalla K, et al: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275:1129-1132, 1997
35. Kluck RM, Bossy-Wetzel E, Green DR, et al: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275:1132-1136, 1997
36. Yoshida H, Kong YY, Yoshida R, et al: Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94:739-750, 1998
37. Cecconi F, Alvarez-Bolado G, Meyer BI, et al: Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 94:727-737, 1998
38. Perkins C, Kim CN, Fang G, et al: Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 58:4561-4566, 1998
39. Spector MS, Desnoyers S, Heoppner DJ, et al: Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature 385:653-656, 1997
40. Chinnaiyan AM, O'Rourke K, Lane BR, et al: Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death. Science 275:1122-1126, 1997
41. Wu D, Wallen HD, Nunez G: Interaction and regulation of subcellular localization of CED-4 by CED-9. Science 275:1126-1129, 1997
42. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994
43. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3:614-620, 1997
44. Henderson S, Huen D, Rowe M, et al: Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A 90:8479-8483, 1993
45. Sarid R, Sato T, Bohenzky RA, et al: Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue. Nat Med 3:293-298, 1997
46. Cheng EH-Y, Nicholas J, Bellows DS, et al: A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A 94:690-694, 1997
47. L, and apaf-1 form a ternary complex. J Biol Chem 273:5841-5845, 1998
48. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A 95:4386-4391, 1998
49. Conradt B, Horvitz H: The C elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell 93:519-529, 1998
50. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 387:773-776, 1997
51. Zha H, Reed JC: Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem 272:31482-31488, 1997
52. L. J Biol Chem 273:8705-8710, 1997
53. Simonian PL, Grillot DA, Nunez G: Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL and Bcl-2. Oncogene 15:1871-1875, 1997
54. Schendel S, Montal M, Reed JC: Bcl-2 family proteins as ion-channels. Cell Death Differ 5:372-380, 1998
55. Rosse T, Olivier R, Monney L, et al: Bcl-2 prolongs cell survival after bax-induced release of cytochrome c. Nature 391:496-499, 1998
56. Jurgensmeier JM, Xie Z, Deveraux Q, et al: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 95:4997-5002, 1998
57. Donovan JJ, Simon MI, Montal M: Requirements for the translocation of diptheria toxin fragment A across lipid membranes. J Biol Chem 260:8817-8823, 1985
58. Reed JC: Cytochrome C: Can't live with it; Can't live without it. Cell 91:559-562, 1997
59. Reed JC: bcl-2 and B-cell neoplasia: Dysregulation of programmed cell death in cancer, in Bertino JR (ed): Encyclopedia of Cancer. San Diego, CA, Academic Press, 1997, pp 125-145
60. Reed JC: Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34:9-19, 1997
61. Reed JC: Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia, in Litwack G (ed): Vitamins and Hormones. San Diego, CA, Academic Press, 1997, pp 99-138
62. Tsujimoto Y, Cossman J, Jaffe E, et al: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985
63. Rampino N, Yamamoto H, Ionov Y, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967-969, 1997
64. Meiijerink JPP, Smetsers TFCM, Slöetjes AW, et al: Bax mutations in cell lines derived from hematological malignancies. Leukemia 9:1828-1832, 1995
65. Yamamoto H, Sawai H, Perucho M: Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 57:4420-4426, 1997
66. Thomas J, Leverrier Y, Marvel J: Bcl-X is the major pleiotropic anti-apoptotic gene activated by retroviral insertion mutagenesis in an IL-3 dependent bone marrow derived cell line. Oncogene 16:1399-1408, 1998
67. Miyashita T, Harigai M, Hanada M, et al: Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res 54:3131-3135, 1994
68. Delia D, Aiello A, Formelli F, et al: Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood 85:59-367, 1995
69. Reed JC: Cell death and the bcl-2 gene. Contemp Oncol 4:29-42, 1994
70. Reed JC: Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541-546, 1995
71. Miyashita T, Reed JC: bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411, 1992
72. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157, 1993
73. Bullock G, Ray S, Reed JC, et al: Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein. Leukemia 10:1731-1740, 1996
74. Tang C, Willingham MC, Reed JC, et al: High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960-1969, 1994
75. Zhan Q, Fan S, Bae I, et al: Induction of BAX by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743-3751, 1994
76. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of BCL-2 and BAX in gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994
77. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of human BAX gene. Cell 80:293-299, 1995
78. Reed JC: Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9:451-474, 1995
79. Strasser A, Huang DCS, Vaux DL: The role of the Bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1333:F151-F178, 1997
80. Reed J: Chronic lymphocytic leukemia: A disease of disregulated programmed cell death. Clin Immunol Newslett 17:125-140, 1998
81. Kaufmann SH, Karp JE, Svingen PA, et al: Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 91:991-1000, 1998
82. Krajewski S, Chatten J, Hanada M, et al: Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Lab Invest 71:42-54, 1995
83. Pepper C, Hoy T, Bentley P: Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 28:355-361, 1998
84. Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400, 1993
85. Krajewski S, Blomqvist C, Franssila K, et al: Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471-4478, 1995
86. Reed JC: Balancing cell life and death: Bax, apoptosis, and breast cancer. J Clin Invest 97:2403-2404, 1996 (editorial; comment)
87. Silvestrini R, Veneroni S, Daidone MG, et al: The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
88. Manne U, Myers RB, Moron C, et al: Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74:346-358, 1997
89. Pezzella F, Turley H, Kuzu I, et al: bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694, 1993
90. Deveraux QL, Reed JC, G.S. S: Caspases and their natural inhibitors as therapeutic targets for regulating apoptosis, in: Handbook of Experimental Pharmacology Proteases as Targets for Therapy (in press)
91. Deveraux Q, Takahashi R, Salvesen GS, et al: X-linked IAP is a direct inhibitor of cell death proteases. Nature 388:300-303, 1997
92. Roy N, Deveraux QL, Takashashi R, et al: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16:6914-6925, 1997
93. Deveraux QL, Roy N, Stennicke HR, et al: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17:2215-2223, 1998
94. Ambrosini G, Adida C, Altieri D: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921, 1997
95. Adida C, Berrebi D, Peuchmaur M, et al: Anti-Apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882-883, 1998 (letter)
96. McCarthy N, Whyte M, Gilbert C, et al: Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. J Cell Biol 136:215-227, 1997
97. Ohta T, Kinoshita T, Naito M, et al: Requirement of the caspase-3/CPP32 protease cascade for apoptotic death following cytokine deprivation in hemotopoietic cells. J Biol Chem 272:23111-23116, 1997
98. Brunet CL, Gunby RH, Benson RSP, et al: Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers. Cell Death Differ 5:107-115, 1998
99. Amarante-Mendes G, Finucane D, Martin S, et al: Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. Cell Death Differ 5:298-306, 1998
100. Hirsch T, Marchetti P, Susin SA, et al: The apoptosis-necrosis paradox: Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 15:1573-1581, 1997
101. Green D, Reed J: Mitochondria and apoptosis. Science 281:1309-1312, 1998
102. Xiang J, Chao DT, Korsmeyer SJ: BAX-induced cell death may not require interleukin 1beta-converting enzyme-like proteases. Proc Natl Acad Sci U S A 93:14559-14563, 1996
103. Cheng EH, Kirsch DG, Clem RJ, et al: Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278:1966-1968, 1997
104. Luo X, Budihardjo I, Zou H, et al: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490, 1998
105. Li H, Zhu H, Xu C, et al: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501, 1998
106. Clem RJ, Cheng EH, Karp CL, et al: Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci U S A 95:554-559, 1998
107. Vaux DL, Strasser A: The molecular biology of apoptosis. Proc Natl Acad Sci U S A 93:2239-2244, 1996
108. Scaffidi C, Fulda S, Srinivasan A, et al: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675-1687, 1998
109. Kuwana T, Smith JJ, Muzio M, et al: Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem 273:16589-16594, 1998
110. Susin S, Zamzami N, Castedo M, et al: The central executioner of apoptosis: Multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med 186:25-37, 1997
111. Marzo I, Brenner C, Zamzami N, et al: The permeability transition pore complex: A target for apoptosis regulation by caspases and Bcl-2-related proteins. J Exp Med 187:1261-1271, 1998
112. Peter ME, Kischkel FC, Scheuerpflug CG, et al: Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur J Immunol 27:1207-1212, 1997
113. Reed J: Promise and problems of Bcl-2 antisense therapy. J Natl Cancer Inst 89:988-990, 1997
114. Webb A, Cunningham D, Cotter F, et al: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137-1141, 1997
115. Muchmore SW, Sattler M, Liang H, et al: X-ray and NMR structure of human Bcl-XL, an inhibitor of programmed cell death. Nature 381:335-341, 1996
116. Sattler M, Liang H, Nettesheim D, et al: Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 275:983-986, 1997
117. Vucic D, Kaiser WJ, Harvey AJ, et al: Inhibition of reaperinduced apoptosis by interaction with inhibitor of apoptosis proteins (IAPs). Proc Natl Acad Sci U S A 94:10183-101838, 1997
118. Vucic D, Kaiser WJ, Miller LK: Inhibitor of apoptosis proteins physically interact with and block apoptosis induced by Drosophila proteins HID and GRIM. Mol Cell Biol 18:3300-3309, 1998
119. Gajewski TF, Thompson CB: Apoptosis meets signal transduction: Elimination of a BAD influence. Cell 87:589-592, 1996
120. Baserga R, Hongo A, Rubini M, et al: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332: D105-F126, 1997
121. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262-267, 1998
122. Marte BM, Downward J: PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 22:355-358, 1997
123. Varner JA, Cheresh DA: Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 69-87, 1996
124. WAF1/CIP1 expression by vascular cell integrin alphavB3 during angiogenesis. J Clin Invest 98:426-433, 1996
125. Bissonnette RP, Exheverri F, Mahboubi A, et al: Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552-554, 1992
126. Fanidi A, Harrington EA, Evan GI: Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554-556, 1992
127. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542, 1994
128. Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619-626, 1994
129. Glinsky GV, Glinsky VV: Apoptosis and metastasis: A superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 101:43-51, 1996
130. Takaoka A, Adachi M, Okuda H, et al: Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 14:2971-2977, 1997